250 related articles for article (PubMed ID: 34091914)
21. TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study.
Zhang Q; Wang Y; Zhang J; Zhang W; Gong J; Ma R
Technol Cancer Res Treat; 2021; 20():15330338211060180. PubMed ID: 34855560
[No Abstract] [Full Text] [Related]
22. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.
Choi BO; Choi IB; Jang HS; Kang YN; Jang JS; Bae SH; Yoon SK; Chai GY; Kang KM
BMC Cancer; 2008 Nov; 8():351. PubMed ID: 19038025
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of High-Intensity Focused Ultrasound for Hepatocellular Carcinoma after Stereotactic Body Radiation Therapy: Initial Experience.
Jin C; Yang W; Ran L; Zhang J; Zhu H
Ultrasound Med Biol; 2020 Oct; 46(10):2744-2751. PubMed ID: 32747074
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Honda Y; Kimura T; Aikata H; Kobayashi T; Fukuhara T; Masaki K; Nakahara T; Naeshiro N; Ono A; Miyaki D; Nagaoki Y; Kawaoka T; Takaki S; Hiramatsu A; Ishikawa M; Kakizawa H; Kenjo M; Takahashi S; Awai K; Nagata Y; Chayama K
J Gastroenterol Hepatol; 2013 Mar; 28(3):530-6. PubMed ID: 23216217
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
26. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies.
Kibe Y; Takeda A; Tsurugai Y; Eriguchi T
Acta Oncol; 2020 Aug; 59(8):888-894. PubMed ID: 32216593
[No Abstract] [Full Text] [Related]
27. Stereotactic body radiation therapy for early hepatocellular carcinoma: a retrospective analysis of the South Australian experience.
Wigg AJ; Narayana SK; Le H; Iankov I; Chinnaratha MA; Tse E; Chen JW; Gowda R
ANZ J Surg; 2019 Sep; 89(9):1138-1143. PubMed ID: 30983104
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation.
Uemura T; Kirichenko A; Bunker M; Vincent M; Machado L; Thai N
World J Surg; 2019 Mar; 43(3):886-893. PubMed ID: 30361748
[TBL] [Abstract][Full Text] [Related]
29. Percutaneous ethanol injection is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation.
Lazzarotto-da-Silva G; Grezzana-Filho TJM; Scaffaro LA; Farenzena M; Silva RK; de Araujo A; Arruda S; Feier FH; Prediger L; Lazzaretti GS; Alvares-da-Silva MR; Chedid AD; Kruel CRP; Chedid MF
Langenbecks Arch Surg; 2023 Jan; 408(1):26. PubMed ID: 36639606
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series.
Wang YF; Dai YH; Lin CS; Chang HC; Shen PC; Yang JF; Hsiang CW; Lo CH; Huang WY
Radiat Oncol; 2021 Jan; 16(1):15. PubMed ID: 33446231
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiotherapy in patients with hepatocellular carcinoma in a multimodal treatment setting.
Gerum S; Heinz C; Belka C; Walter F; Paprottka PM; De Toni EN; Roeder F
Strahlenther Onkol; 2020 Apr; 196(4):334-348. PubMed ID: 31732784
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma.
Que J; Kuo HT; Lin LC; Lin KL; Lin CH; Lin YW; Yang CC
BMC Cancer; 2016 Jul; 16():451. PubMed ID: 27405814
[TBL] [Abstract][Full Text] [Related]
33. Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT).
Murray LJ; Sykes J; Brierley J; Kim JJ; Wong RKS; Ringash J; Craig T; Velec M; Lindsay P; Knox JJ; Dawson LA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):900-909. PubMed ID: 29976502
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization.
Kang JK; Kim MS; Cho CK; Yang KM; Yoo HJ; Kim JH; Bae SH; Jung DH; Kim KB; Lee DH; Han CJ; Kim J; Park SC; Kim YH
Cancer; 2012 Nov; 118(21):5424-31. PubMed ID: 22570179
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm.
Jacob R; Turley F; Redden DT; Saddekni S; Aal AK; Keene K; Yang E; Zarzour J; Bolus D; Smith JK; Gray S; White J; Eckhoff DE; DuBay DA
HPB (Oxford); 2015 Feb; 17(2):140-9. PubMed ID: 25186290
[TBL] [Abstract][Full Text] [Related]
36. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
[TBL] [Abstract][Full Text] [Related]
37. Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial.
Chen LC; Chiou WY; Lin HY; Lee MS; Lo YC; Huang LW; Chang CM; Hung TH; Lin CW; Tseng KC; Liu DW; Hsu FC; Hung SK
BMC Cancer; 2019 Mar; 19(1):275. PubMed ID: 30922261
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma.
Shin HS; Hwan Lee S; Jun BG; Kim HS; Kang SH; Park JY; Choi SI; Cheon GJ; Kim YD; Yoo JJ; Kim SG; Kim YS; Jeong SW; Jang JY; Suk KT; Kim DJ; Jo IY; Won YK
Eur J Gastroenterol Hepatol; 2022 Nov; 34(11):1187-1194. PubMed ID: 36170689
[TBL] [Abstract][Full Text] [Related]
39. Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas.
Cheung TT; Poon RT; Jenkins CR; Chu FS; Chok KS; Chan AC; Tsang SH; Dai WC; Yau TC; Chan SC; Fan ST; Lo CM
Liver Int; 2014 Jul; 34(6):e136-43. PubMed ID: 24451026
[TBL] [Abstract][Full Text] [Related]
40. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.
Graziadei IW; Sandmueller H; Waldenberger P; Koenigsrainer A; Nachbaur K; Jaschke W; Margreiter R; Vogel W
Liver Transpl; 2003 Jun; 9(6):557-63. PubMed ID: 12783395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
